VLA 15
Alternative Names: Borrelia vaccine - GlaxoSmithKline/Valneva; Lyme borreliosis vaccine - GlaxoSmithKline/Valneva; Lyme-borreliosis-vaccine-Valneva; Lyme-disease-vaccine-GlaxoSmithKline/Valneva; Lyme-disease-vaccine-Valneva; PF-07307405; VLA 15Latest Information Update: 06 Dec 2023
At a glance
- Originator Intercell
- Developer Pfizer; Valneva
- Class Bacterial vaccines; Lyme disease vaccines; Subunit vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Lyme disease
Most Recent Events
- 04 Dec 2023 Pfizer and Valneva completes enrolment in the phase III VALOR trial in Lyme disease (In adolescents, In adults, In children, Prevention, In the elderly) in Germany, Finland, the Netherlands, Poland, Sweden, Estonia, Canada, USA (IM) (NCT05477524) (EudraCT2021-005427-20)
- 07 Sep 2023 Safety and immunogenicity data from a phase II VLA15-221 trial in Lyme disease released by Valneva and Pfizer
- 04 May 2023 Pfizer announces intention to submit Biologics License Application to US FDA for Lyme disease in 2026